- News Releases
-
- Mar. 31, 2020 (PDF/51KB)Licensing
- Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
-
- Mar. 31, 2020 (PDF/85KB)CSR
- Donations to the Kitasato Institute's Project for COVID-19 for Early Identification of Therapeutic Medicine for its Treatment
-
- Mar. 25, 2020 (PDF/164KB)Products
- Sumitomo Dainippon Pharma Announces the Approval of RETHIO for an Additional Indication of Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
-
- Mar. 25, 2020 (PDF/107KB)Products
- Sumitomo Dainippon Pharma Announces Approval of Atypical Antipsychotic Agent, LATUDA Tablets in Japan
-
- Mar. 18, 2020 (PDF/83KB)Corporate
- Sumitomo Dainippon Pharma Announces Change in Executive Officer and Other Key Position
Other Notices
-
- Dec. 02, 2019Others
- Posted Factbook 2019 ver.2
-
- Sep. 30, 2019Others
- Posted Integrated Report 2019
-
- Jun. 28, 2019Others
- Posted FactBook 2019
IR Library
-
Aiming to create innovative pharmaceutical products
-
Targeting sustainable growth
-
Leading our global expansion